Liu et al. [35] presented data on the combination of the extracellular signal-regulated mitogen-activated kinase (MEK) inhibitor, trametinib, which has already demonstrated efficacy in patients with advanced melanoma, and Tim-3. The gene discussed is HAVCR2; the disease is melanoma.